These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15452186)

  • 1. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit.
    Steiner HH; Bonsanto MM; Beckhove P; Brysch M; Geletneky K; Ahmadi R; Schuele-Freyer R; Kremer P; Ranaie G; Matejic D; Bauer H; Kiessling M; Kunze S; Schirrmacher V; Herold-Mende C
    J Clin Oncol; 2004 Nov; 22(21):4272-81. PubMed ID: 15452186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells.
    Karcher J; Dyckhoff G; Beckhove P; Reisser C; Brysch M; Ziouta Y; Helmke BH; Weidauer H; Schirrmacher V; Herold-Mende C
    Cancer Res; 2004 Nov; 64(21):8057-61. PubMed ID: 15520216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward a glioblastoma vaccine: promise and potential pitfalls.
    Fine HA
    J Clin Oncol; 2004 Nov; 22(21):4240-3. PubMed ID: 15452184
    [No Abstract]   [Full Text] [Related]  

  • 4. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment.
    Liau LM; Prins RM; Kiertscher SM; Odesa SK; Kremen TJ; Giovannone AJ; Lin JW; Chute DJ; Mischel PS; Cloughesy TF; Roth MD
    Clin Cancer Res; 2005 Aug; 11(15):5515-25. PubMed ID: 16061868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination.
    Wheeler CJ; Das A; Liu G; Yu JS; Black KL
    Clin Cancer Res; 2004 Aug; 10(16):5316-26. PubMed ID: 15328167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor immunization of head and neck squamous cell carcinoma patients with a virus-modified autologous tumor cell vaccine.
    Herold-Mende C; Karcher J; Dyckhoff G; Schirrmacher V
    Adv Otorhinolaryngol; 2005; 62():173-83. PubMed ID: 15608427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients.
    Wheeler CJ; Black KL; Liu G; Mazer M; Zhang XX; Pepkowitz S; Goldfinger D; Ng H; Irvin D; Yu JS
    Cancer Res; 2008 Jul; 68(14):5955-64. PubMed ID: 18632651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
    Tang J; Flomenberg P; Harshyne L; Kenyon L; Andrews DW
    Clin Cancer Res; 2005 Jul; 11(14):5292-9. PubMed ID: 16033848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.
    De Vleeschouwer S; Fieuws S; Rutkowski S; Van Calenbergh F; Van Loon J; Goffin J; Sciot R; Wilms G; Demaerel P; Warmuth-Metz M; Soerensen N; Wolff JE; Wagner S; Kaempgen E; Van Gool SW
    Clin Cancer Res; 2008 May; 14(10):3098-104. PubMed ID: 18483377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine].
    Ma J; Wang YL; Hu HM; Fox BA; Si LS
    Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
    López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
    J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
    Chang GC; Lan HC; Juang SH; Wu YC; Lee HC; Hung YM; Yang HY; Whang-Peng J; Liu KJ
    Cancer; 2005 Feb; 103(4):763-71. PubMed ID: 15637694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma.
    Jie X; Hua L; Jiang W; Feng F; Feng G; Hua Z
    Cell Biochem Biophys; 2012 Jan; 62(1):91-9. PubMed ID: 21909820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study.
    Stojadinovic A; Mittendorf EA; Holmes JP; Amin A; Hueman MT; Ponniah S; Peoples GE
    Ann Surg Oncol; 2007 Dec; 14(12):3359-68. PubMed ID: 17906897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data.
    Morita S; Oka Y; Tsuboi A; Kawakami M; Maruno M; Izumoto S; Osaki T; Taguchi T; Ueda T; Myoui A; Nishida S; Shirakata T; Ohno S; Oji Y; Aozasa K; Hatazawa J; Udaka K; Yoshikawa H; Yoshimine T; Noguchi S; Kawase I; Nakatsuka S; Sugiyama H; Sakamoto J
    Jpn J Clin Oncol; 2006 Apr; 36(4):231-6. PubMed ID: 16611662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
    Peoples GE; Gurney JM; Hueman MT; Woll MM; Ryan GB; Storrer CE; Fisher C; Shriver CD; Ioannides CG; Ponniah S
    J Clin Oncol; 2005 Oct; 23(30):7536-45. PubMed ID: 16157940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma.
    Ockert D; Schirrmacher V; Beck N; Stoelben E; Ahlert T; Flechtenmacher J; Hagmüller E; Buchcik R; Nagel M; Saeger HD
    Clin Cancer Res; 1996 Jan; 2(1):21-8. PubMed ID: 9816085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.
    Fishman M; Hunter TB; Soliman H; Thompson P; Dunn M; Smilee R; Farmelo MJ; Noyes DR; Mahany JJ; Lee JH; Cantor A; Messina J; Seigne J; Pow-Sang J; Janssen W; Antonia SJ
    J Immunother; 2008 Jan; 31(1):72-80. PubMed ID: 18157014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
    Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.